Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe in hypercholesterolaemia.

M Farnier1

  • 1Point Médical, Dijon, France.

International Journal of Clinical Practice
|November 12, 2002
PubMed
Summary
This summary is machine-generated.

Ezetimibe effectively lowers LDL cholesterol by inhibiting intestinal cholesterol absorption. When combined with statins, it provides an additive LDL-C reduction, offering a simpler treatment approach.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Familial hypercholesterolemia: A largely underestimated cardiovascular risk].

Annales de cardiologie et d'angeiologie·2017
Same author

Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects.

Atherosclerosis·2014
Same author

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.

Diabetes, obesity & metabolism·2011
Same author

[Recommendations for children with hypercholesterolemia].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2010
Same author

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.

International journal of clinical practice·2009
Same author

[Dyslipidemia and abdominal obesity: mechanisms and characteristics (Part I)].

Archives des maladies du coeur et des vaisseaux·2008
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Ezetimibe represents a novel class of cholesterol absorption inhibitors.
  • It selectively blocks intestinal cholesterol absorption without impacting fat-soluble vitamin or triglyceride uptake.

Purpose of the Study:

  • To evaluate the efficacy and safety of ezetimibe monotherapy.
  • To assess potential interactions and combined efficacy/safety of ezetimibe with statins.

Main Methods:

  • Phase II/III clinical trials for monotherapy efficacy and safety.
  • Phase I/II studies to investigate pharmacokinetic/pharmacodynamic interactions with statins.

Main Results:

  • Ezetimibe 10 mg/day significantly reduced LDL-cholesterol by 17.4-18.5% and increased HDL-cholesterol by 3.5%.

Related Experiment Videos

  • Co-administration with statins resulted in an additive 18% LDL-C reduction without significant pharmacokinetic interactions.

    • Conclusions:

    • Ezetimibe monotherapy demonstrates favorable lipid-lowering effects and an excellent safety profile.
    • Combination therapy with statins offers enhanced LDL-C reduction in a single step, simplifying treatment regimens.